

**CNQ Symbol – “GNSE”  
PRESS RELEASE 06-08**

**IMMUNALL SCIENCE INC. MANAGEMENT CEASE TRADE ORDER (MCTO) LIFTED.**

June 27, 2008.

As of June 23rd, 2008. Immunall Science Inc.(the “Corporation”) filed it’s audited annual and interim financial statements and the Management Discussion and Analysis with the Alberta Securities Commission and the British Columbia Securities Commission. These statements were overdue and the Corporation had been subject to a Management Cease Trade under the provisions of CSA Staff Notice57-301.

Since the audited annual financial statements and Management Discussion and Analysis for the year ended December 31,2007 and the interim financial statements and Management Discussion and Analysis for the quarter ended March 31, 2008 have been filed in full accordance of the filing requirements, the Alberta Securities Commission, and the British Columbia Securities Commission have now lifted the Management Cease Trade Order.

**About Immunall Science Inc.**

Immunall Science Inc. (ISI) uses a patented process for extracting certain components from the American Ginseng which have shown to strengthen the immune system in humans and animals. The product ginse’ (pronounced jin’say) will be marketed to companies for inclusion in current products a value added ingredient or as a new stand-alone product.

**The CNQ EXCHANGE, INC HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILTY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**

For further information: M Frank Phillet, Chief Operating Officer  
Tel (780) 718-6603 Fax (780) 421-9262, Email frank.phillet@ginse.ca